SS/NEisSlc |
systolic blood pressure |
controlled cilazapril content drinking water (2.5 ug/ml) (for 547.5 days) |
Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. |
arterial blood pressure trait |
not specified |
547 days
| 10 |
136.0 |
mmHg |
3.0 |
9.49 |
vascular indwelling catheter method |
femoral artery |
0.0 |
|
0 |
|
|
|
106788 |
2339 |
SS/NEisSlc |
serum NAG activity level |
controlled cilazapril content drinking water (0.94 mg/kg/d) (for 547.5 days) |
Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. |
blood enzyme amount |
not specified |
547 days
| 10 |
17.0 |
uU/ml |
0.9 |
2.85 |
blood NAG activity assay |
|
0.0 |
|
0 |
|
blood NAG activity assay (MMO:0000723) |
serum NAG activity level (CMO:0003487) |
107427 |
2339 |
SS/NEisSlc |
neuron count |
controlled cilazapril content drinking water (0.16 mg/kg/d) (for 547.5 days) |
Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. |
hippocampus neuron quantity |
not specified |
547 days
| 10 |
1466.0 |
cells/mm2 |
42.0 |
132.82 |
ex vivo light microscopy with histochemistry |
|
0.0 |
|
0 |
|
|
|
107466 |
2339 |
SS/NEisSlc |
water drink intake rate |
controlled cilazapril content drinking water (2.5 ug/ml) (for 547.5 days) |
Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. |
drinking behavior trait |
not specified |
547 days
| 10 |
35.1 |
ml/d |
3.2 |
10.12 |
drink intake measuring method |
|
0.0 |
|
0 |
|
|
|
106785 |
2339 |
SS/NEisSlc |
water drink intake rate |
controlled cilazapril content drinking water (12.5 ug/ml) (for 547.5 days) |
Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. |
drinking behavior trait |
not specified |
547 days
| 10 |
40.5 |
ml/d |
5.4 |
17.08 |
drink intake measuring method |
|
0.0 |
|
0 |
|
|
|
106786 |
2339 |
SS/NEisSlc |
systolic blood pressure |
controlled cilazapril content drinking water (12.5 ug/ml) (for 547.5 days) |
Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. |
arterial blood pressure trait |
not specified |
547 days
| 10 |
122.0 |
mmHg |
4.0 |
12.65 |
vascular indwelling catheter method |
femoral artery |
0.0 |
|
0 |
|
|
|
106789 |
2339 |
SS/NEisSlc |
urine total protein excretion rate |
controlled cilazapril content drinking water (0.16 mg/kg/d) (for 547.5 days) |
Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. |
total urine protein amount |
not specified |
547 days
| 10 |
204.8 |
mg/d |
16.0 |
50.6 |
urine total protein analysis |
|
0.0 |
|
0 |
|
|
|
107438 |
2339 |
SS/NEisSlc |
time to first movement outside a discrete space in an experimental apparatus |
controlled cilazapril content drinking water (0.94 mg/kg/d) (for 547.5 days) then tactile electric shock exposure (500 mA) (for 0 hours) |
Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. |
locomotor behavior trait |
not specified |
63 days-236 days |
10 |
397.0 |
s |
3.0 |
9.49 |
passive avoidance test using a two-way shuttle box apparatus |
|
0.0 |
electric foot shock |
18 |
days |
passive avoidance test using a two-way shuttle box apparatus (MMO:0000725) |
|
107470 |
2339 |
SS/NEisSlc |
serum NAG activity level |
controlled cilazapril content drinking water (0.16 mg/kg/d) (for 547.5 days) |
Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. |
blood enzyme amount |
not specified |
547 days
| 10 |
19.1 |
uU/ml |
1.7 |
5.38 |
blood NAG activity assay |
|
0.0 |
|
0 |
|
blood NAG activity assay (MMO:0000723) |
serum NAG activity level (CMO:0003487) |
107426 |
2339 |
SS/NEisSlc |
heart weight to body weight ratio |
controlled cilazapril content drinking water (0.94 mg/kg/d) (for 547.5 days) |
Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. |
heart mass |
not specified |
547 days
| 10 |
2.8 |
g/kg |
0.1 |
0.32 |
post excision weight measurement |
|
0.0 |
|
0 |
|
|
|
106794 |
2339 |
SS/NEisSlc |
timed urine volume to body weight ratio |
controlled cilazapril content drinking water (0.94 mg/kg/d) (for 547.5 days) |
Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. |
urine output |
not specified |
547 days
| 10 |
0.02 |
ul/min/g |
0.0 |
0.01 |
urine volume measurement method |
|
0.0 |
|
0 |
|
|
|
107431 |
2339 |
SS/NEisSlc |
creatinine clearance to body weight ratio |
controlled cilazapril content drinking water (0.16 mg/kg/d) (for 547.5 days) |
Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. |
glomerular filtration trait |
not specified |
547 days
| 10 |
0.42 |
ml/min/100g |
0.02 |
0.07 |
plasma creatinine analysis |
|
0.0 |
|
0 |
|
|
|
107442 |
2339 |
SS/NEisSlc |
plasma creatinine level |
controlled cilazapril content drinking water (0.16 mg/kg/d) (for 547.5 days) |
Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. |
blood creatinine amount |
not specified |
547 days
| 10 |
0.51 |
mg/dl |
0.02 |
0.06 |
plasma creatinine analysis |
|
0.0 |
|
0 |
|
|
|
107422 |
2339 |
SS/NEisSlc |
plasma creatinine level |
controlled cilazapril content drinking water (0.94 mg/kg/d) (for 547.5 days) |
Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. |
blood creatinine amount |
not specified |
547 days
| 10 |
0.49 |
mg/dl |
0.0 |
0.0 |
plasma creatinine analysis |
|
0.0 |
|
0 |
|
|
|
107423 |
2339 |
SS/NEisSlc |
urine total protein excretion rate |
controlled cilazapril content drinking water (0.94 mg/kg/d) (for 547.5 days) |
Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. |
total urine protein amount |
not specified |
547 days
| 10 |
182.9 |
mg/d |
12.1 |
38.26 |
urine total protein analysis |
|
0.0 |
|
0 |
|
|
|
107439 |
2339 |
SS/NEisSlc |
neuron count |
controlled cilazapril content drinking water (0.94 mg/kg/d) (for 547.5 days) |
Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. |
hippocampus neuron quantity |
not specified |
547 days
| 10 |
1491.0 |
cells/mm2 |
57.0 |
180.25 |
ex vivo light microscopy with histochemistry |
|
0.0 |
|
0 |
|
|
|
107467 |
2339 |
SS/NEisSlc |
heart weight to body weight ratio |
controlled cilazapril content drinking water (0.16 mg/kg/d) (for 547.5 days) |
Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. |
heart mass |
not specified |
547 days
| 10 |
3.0 |
g/kg |
0.1 |
0.32 |
post excision weight measurement |
|
0.0 |
|
0 |
|
|
|
106793 |
2339 |
SS/NEisSlc |
time to first movement outside a discrete space in an experimental apparatus |
controlled cilazapril content drinking water (0.16 mg/kg/d) (for 547.5 days) then tactile electric shock exposure (500 mA) (for 0 hours) |
Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. |
locomotor behavior trait |
not specified |
63 days-236 days |
10 |
389.0 |
s |
11.0 |
34.79 |
passive avoidance test using a two-way shuttle box apparatus |
|
0.0 |
electric foot shock |
18 |
days |
passive avoidance test using a two-way shuttle box apparatus (MMO:0000725) |
|
107469 |
2339 |
SS/NEisSlc |
timed urine volume to body weight ratio |
controlled cilazapril content drinking water (0.16 mg/kg/d) (for 547.5 days) |
Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. |
urine output |
not specified |
547 days
| 10 |
0.02 |
ul/min/g |
0.0 |
0.0 |
urine volume measurement method |
|
0.0 |
|
0 |
|
|
|
107430 |
2339 |
SS/NEisSlc |
creatinine clearance to body weight ratio |
controlled cilazapril content drinking water (0.94 mg/kg/d) (for 547.5 days) |
Hirawa N, et al., Hypertension. 1999 Sep;34(3):496-502. |
glomerular filtration trait |
not specified |
547 days
| 10 |
0.45 |
ml/min/100g |
0.07 |
0.22 |
plasma creatinine analysis |
|
0.0 |
|
0 |
|
|
|
107443 |
2339 |